Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.
about
Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and RehabilitationMechanisms of altered redox regulation in neurodegenerative diseases--focus on S--glutathionylationPotential for developing purinergic drugs for gastrointestinal diseasesAllosteric mechanisms within the adenosine A2A-dopamine D2 receptor heterotetramerUnprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's diseaseAdenosine receptors as drug targets--what are the challenges?Adenosine signaling during acute and chronic disease statesThe GPCR heterotetramer: challenging classical pharmacology.Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramerMechanisms of the psychostimulant effects of caffeine: implications for substance use disorders.8-Benzyltetrahydropyrazino[2,1-f]purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases.Binding of the Antagonist Caffeine to the Human Adenosine Receptor hA2AR in Nearly Physiological ConditionsMedicinal chemistry of adenosine, P2Y and P2X receptors.The Role of DNA Methylation and Histone Modifications in Neurodegenerative Diseases: A Systematic ReviewModeling Parkinson's disease in monkeys for translational studies, a critical analysis.G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Structure-function studies with G protein-coupled receptors as a paradigm for improving drug discovery and development of therapeutics.Dopamine receptor agonists for Parkinson's disease.Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.Moonlighting adenosine deaminase: a target protein for drug development.Insights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes.History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A 2A adenosine receptor binding site.Signaling within Allosteric Machines: Signal Transmission Pathways Inside G Protein-Coupled Receptors.Adenosine A1 and A2A Receptors in the Brain: Current Research and Their Role in Neurodegeneration.Multivalent approaches and beyond: novel tools for the investigation of dopamine D2 receptor pharmacology.How does adenosine control neuronal dysfunction and neurodegeneration?Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.The role of 5-arylalkylamino- and 5-piperazino- moieties on the 7-aminopyrazolo[4,3-d]pyrimidine core in affecting adenosine A1 and A2A receptor affinity and selectivity profiles.Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.Pathological overproduction: the bad side of adenosine.Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.Adenosine and its receptors as therapeutic targets: An overview.Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.A2A Receptor Antagonists May Potentially Treat Parkinson's Disease.Description of a bivalent cannabinoid ligand with hypophagic properties.Behavioral control by striatal adenosine A2A -dopamine D2 receptor heteromers.Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners.
P2860
Q26745654-2B8F83BA-8B93-41D2-BFF5-EB550E4A120EQ26830954-FB98838D-3915-4B75-A421-6D9B43C27F87Q27000719-B2AF7B3F-7929-4937-80F2-7CB91FFB46D8Q28263053-C0666CDE-310C-4294-B143-622CD0B0A90BQ28542729-A27B40B6-93B3-49D4-A5E7-3ED7A051658BQ29346491-037D7494-2F5D-488C-8812-9F387C0572C3Q34035228-B2AAF3D9-C1A0-4AAA-A39E-1F11BA8CB023Q34463989-169A00C8-B286-48B2-8062-ACB7EF859EE2Q34481913-E8A723FC-D6D6-41E9-9D0F-E43F8466F7C8Q34509861-0FCEC12F-E4FE-48A3-8CFF-DE8C7051FC7BQ35166780-7FFC4352-39CC-4AC4-B6A9-2C9323768E7DQ35636233-47A4522F-3C86-423B-A841-F2EE122610E7Q35873582-D6022C68-74F4-4D6B-BA15-69322B6D3583Q36223734-71559B48-D6A7-4071-AA9C-7C31EE21EF13Q37656643-BFC73F4F-4523-48D6-BF7F-37C25E33AAAFQ37680849-78AC26EF-6005-4D83-8041-0729F07660A0Q37717872-172651AE-206D-4ECB-AAC8-7AA87AA99DEBQ38022265-4914CEBF-8A30-4AD1-9315-733804EBCE66Q38065136-028F95DA-9520-4DE6-9219-8D6C82AA324FQ38169202-D00BF794-D743-4FA7-90DA-43F832E52F5FQ38200930-F2CFE1B1-1103-4007-A06E-6E17AA778FEAQ38220597-A4757F26-A5A4-44D1-8D8F-E00A40E05AACQ38247995-7F824995-4A79-45B4-B0CC-C638AA861245Q38395423-9DC228FA-A8BF-4692-BE14-5FD3A0EDCAF0Q38661496-0A602FEA-ABBE-4B41-83DC-CF432A6D9AB8Q38675922-D771DC13-29AB-4BF1-9E06-4315066AE94CQ38691042-93EA2C5B-2613-4355-9677-BB9AC767D29CQ38846984-A1FEC25D-D35F-4D3E-B9EB-73237D0D1DFAQ38882782-50D0CB4C-558F-462F-A136-135FF755479DQ38931189-2BA382EF-9BE2-4652-B4A6-B46BE98F16B5Q39003888-EA96BDB6-EED7-4819-ABEB-06D50A82EAACQ39008496-2E3FF0C6-AB57-4994-846E-623D227A18D0Q39157893-A30BC172-2322-4992-A2B2-FB0D6038D68BQ40781522-D017C95E-028D-421F-BBBB-740993DA7549Q42059361-12F6B4C6-2479-4FD2-A241-354F16E24B1AQ42512289-30AB5781-CEE2-4F0F-BBF3-6FC946396D22Q43102001-C12D72FF-6724-43E0-8943-04C3BCAEC0A0Q45840317-5FCB9D09-3BD7-4CEA-9D9A-8A806A7C3903Q47624646-AFB143EB-7486-4C21-8818-BDF4BA0503AAQ47751959-4BEEC333-6CE9-423F-A65F-109ED00C2454
P2860
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Past, present and future of A( ...... herapy of Parkinson's disease.
@ast
Past, present and future of A( ...... herapy of Parkinson's disease.
@en
type
label
Past, present and future of A( ...... herapy of Parkinson's disease.
@ast
Past, present and future of A( ...... herapy of Parkinson's disease.
@en
prefLabel
Past, present and future of A( ...... herapy of Parkinson's disease.
@ast
Past, present and future of A( ...... herapy of Parkinson's disease.
@en
P2860
P50
P1476
Past, present and future of A( ...... therapy of Parkinson's disease
@en
P2093
Marie Therese Armentero
P2860
P304
P356
10.1016/J.PHARMTHERA.2011.07.004
P577
2011-07-23T00:00:00Z